Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Clinical trial NCT05482893 · RECRUITING

Trial details

NCT number: NCT05482893
Sponsor: Phanes Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Gastric or Gastroesophageal Junction Adenocarcinoma Pancreatic Ductal Adenocarcinoma Biliary Tract Cancer (BTC)

Start date: 2023-03-15
Primary completion: 2027-12-01
Enrollment: 258

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.